8AP.F Agios Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
28.40 EUR
Close of Nov 12, 2026
19.70 38.80
Market cap
EUR 1.70B
P/E
-
P/B
1.86x
ROE
-36.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 8AP.F undervalued?

Graham number

The Graham number of Agios Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Agios Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Agios Pharmaceuticals Inc yet.

Agios Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of …

Full company profile